US moves to restrict federal funding for gender-affirming care for minors amid medical and political debate

The Trump administration has announced plans to cut federal funding for puberty blockers, hormone therapy, and gender-related surgeries for minors, igniting a heated political and medical controversy over the treatment of children with gender dysphoria.

The Trump administration has moved to cut off federal funding for puberty blockers, hormone therapy and gender-related surgeries for minors through Medicaid and the Children’s Health Insurance Program, a step that has sharpened a wider political and medical fight over how to treat children with gender dysphoria. A senior Health and Human Services official defended the policy on Tuesday, arguing that counselling and family support should come before medical intervention. According to HHS, the rule does not outlaw the procedures outright, but it would prevent federal dollars from paying for them.

Adm. Brian Christine, the assistant secretary for health at HHS, said in an interview with Fox News Digital that the administration was acting out of concern for children who may later regret treatments with lasting effects. Christine, a urologist who also leads the US Public Health Service Commissioned Corps, said the department sees mental health care as the proper first response. He also argued that the rise in diagnoses among minors cannot be explained by epidemiology alone and described the trend as a form of social contagion.

The administration’s position mirrors a broader effort inside HHS and the White House to recast these treatments as unsafe and experimental. In its announcement, the Centres for Medicare & Medicaid Services said the funding change is meant to follow the science, protect children from potentially irreversible harm and save taxpayer money. HHS has also said hospitals should not perform so-called sex-rejecting procedures on children, while the White House has described the issue as a grave misuse of medicine.

The new rule is due to take effect on October 13 and includes a six-month tapering period for children already receiving hormone therapy, according to CMS. That means patients currently on treatment would not be forced to stop abruptly, a detail the agency says is intended to reduce immediate harm. The administration’s move comes as 27 states have already enacted some form of restriction on gender-affirming care for minors, according to KFF, underscoring how quickly the issue has become a national regulatory fight.

Supporters of gender-affirming care say major medical groups still view it as an accepted model of treatment for some young people with persistent gender dysphoria. But the Trump administration has rejected that view and instead points to its own review of evidence, which it says found serious long-term risks including infertility and other irreversible effects. Christine said the science supports counselling and compassionate care, not medical procedures that can permanently alter a child’s body.